Last reviewed · How we verify

NCT05538741

Hypotension After Anesthetic Induction with Remimazolam in Elderly

Completed NA Last updated 19 September 2024
What this trial tests

NA trial testing Bolus of remimazolam in Hypotension in 62 participants. Completed in 14 June 2024.

Timeline
14 July 2023
Primary endpoint
14 June 2024
14 June 2024

Quick facts

Lead sponsorKangbuk Samsung Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposeother
Enrollment62
Start date14 July 2023
Primary completion14 June 2024
Estimated completion14 June 2024
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Kangbuk Samsung Hospital

Who can join

60 and older, any sex, with Hypotension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Even though remimazolam is known to be safely administered without hemodynamic instability, hypotension is the one of the common side effects of remimazolam. Because elderly patients are susceptible to hypotension due to old age, multimodality, and multiple medications, hypotension can be harmful in elderly patients. Remimazolam can be administered either bolus or continuous for anesthetic induction. In our study the investigators aimed to compare the incidence of hypotension after anesthetic induction using remimazolam by bolus injection and continuous infusion in elderly patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hypotension

Currently open trials in the same condition.

Other Kangbuk Samsung Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05538741.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing